A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

MLA

Youram Nassir, et al. “A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.” Blood, vol. 120, Nov. 2012, p. 2979. EBSCOhost, https://doi.org/10.1182/blood.v120.21.2979.2979.

APA

Youram Nassir, Leonard M. Klein, Marshall S. Flam, Alberto Bessudo, Thomas B. S. Woliver, Robert Vescio, Regina A. Swift, Shahrooz Eshaghian, Peter Rosen, James R. Berenson, & Laura Stampleman. (2012). A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma. Blood, 120, 2979. https://doi.org/10.1182/blood.v120.21.2979.2979

Chicago

Youram Nassir, Leonard M. Klein, Marshall S. Flam, Alberto Bessudo, Thomas B. S. Woliver, Robert Vescio, Regina A. Swift, et al. 2012. “A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.” Blood 120 (November): 2979. doi:10.1182/blood.v120.21.2979.2979.